ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: 0340 • ACR Convergence 2022

    Birth Order Is a Risk Factor for Systemic Lupus Erythematosus

    Nicole Shammas1, Priya Ramani2, Christopher Aston3, Ana Quintero-Del-Rio4, Judith James5, John Harley6, Isaac Harley7 and Hal Scofield5, 1University of Colorado School of Medicine, Aurora, CO, 2Tampa Rheumatology, Tampa, FL, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4OU Children's Hospital, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Birth order effects have been described in several immune and non-immune disease states. While some studies have found an increased risk of developing autoimmune…
  • Abstract Number: 1026 • ACR Convergence 2022

    Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis

    Paras Karmacharya1, Courtney Stull2, Alisa Stephens-Shields3, M. Elaine Husni4, Jose Scher5, Ethan Craig6, Robert Fitzsimmons3, Soumya Reddy7, Marina Magrey8, Alexis Ogdie9 and Jessica Walsh10, 1Vanderbilt University, Nashville, TN, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, 4Cleveland Clinic, Cleveland, OH, 5New York University School of Medicine, New York, NY, 6University of Pennsylvania, Wallingford, PA, 7NYU School of Medicine, New York, NY, 8Case Western Reserve University, University Hospitals, Richfield, OH, 9Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 10University of Utah, Salt Lake City, UT

    Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…
  • Abstract Number: 1371 • ACR Convergence 2022

    Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus

    Amita Aggarwal1, Liza Rajasekhar2, Parasar Ghosh3, Ashish J Mathew4, Chengappa Kavadichanda5, Vineetha Shobha6, Ranjan Gupta7, Saumya Ranjan Tripathy8, Manish Rathi9, Avinash Jain10 and Able Lawrence1, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Nizam's Institute of Medical Sciences, Madhapur, India, 3Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 4Rigshospitalet, Copenhagen, Denmark, 5JIPMER, Pondicherry, Puducherry, India, 6St. John’s Medical College Hospital, Bangalore, India, 7All India Institute of Medical Sciences, New Delhi, India, 8SCB medical college, Cuttack, India, 9PGIMER Chandigarh, Chandigarh, India, 10SMS Medical College, Lucknow, India

    Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…
  • Abstract Number: 1815 • ACR Convergence 2022

    Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease

    Gary Ho1, Michael Toprover2, Daria Crittenden3, binita Shah4 and Michael Pillinger5, 1New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 2Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, 3CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, 4New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, 5NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
  • Abstract Number: 2073 • ACR Convergence 2022

    The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies

    Laurence S Magder1, Andrea Fava2, Daniel W. Goldman3 and Michelle Petri3, 1University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
  • Abstract Number: 0347 • ACR Convergence 2022

    Real-World Effectiveness of Belimumab in Patients with SLE in the United States

    Christopher Bell1, Bernie Rubin2, Karen Worley3, Guillaume Germain4, François Laliberté4, Sean D. MacKnight4, Ana Urosevic4 and Mei Sheng Duh5, 1GlaxoSmithKline, US Value, Evidence and Outcomes, Research Triangle Park, NC, 2GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, 3GlaxoSmithKline, US Value, Evidence and Outcomes, Cincinnati, OH, 4Groupe d’analyse, Montréal, QC, Canada, 5Analysis Group Inc, Boston, MA

    Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…
  • Abstract Number: 1034 • ACR Convergence 2022

    Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice

    Kathryn Starzyk, Pam Kumparatana and roger Meng, OM1, Inc., Boston, MA

    Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
  • Abstract Number: 1395 • ACR Convergence 2022

    Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis

    Yao-Fan Fang1 and Lai-Chu See2, 1Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan

    Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
  • Abstract Number: 1845 • ACR Convergence 2022

    Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study

    Pamela Doti1, Ana Luisa Cunha2, Armin Quispe Cornejo3, Ángela Nieto González1, Andre Matos1, Pedro Guevara Hernández1, Pedro Castro Rebollo1 and Gerard Espinosa Garriga1, 1Hospital Clínic, Barcelona, Spain, 2Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, 3Erasme Hospital, Brussels, Belgium

    Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…
  • Abstract Number: 2075 • ACR Convergence 2022

    Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids

    MI HYEON KIM1, Eun Bong Lee1, Eun Young Lee2, Jin Kyun Park3 and Jun Won Park1, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul National University College of Medicine, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea

    Background/Purpose: This study aimed to investigate the incidence and risk factors of bloodstream infection (BSI) in patients with systemic lupus erythematosus (SLE) receiving moderate-to-high dose…
  • Abstract Number: 0467 • ACR Convergence 2022

    All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study

    Jacob Sode1, Jens Rathmann1, Anna Wilding2, Carl Turesson3 and Aladdin Mohammad1, 1Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 2Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
  • Abstract Number: 1068 • ACR Convergence 2022

    Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype

    Maria Herran1, Brit Adler2, Jamie Perin3, Walter Morales4, Mark Pimentel5 and Zsuzsanna McMahan6, 1School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, 2Johns Hopkins University, Division of Rheumatology, Baltimore, MD, 3John Hopkins University, Baltimore, MD, 4Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, 5Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, 6Johns Hopkins Rheumatology, Baltimore, MD

    Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…
  • Abstract Number: 1443 • ACR Convergence 2022

    Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features

    Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…
  • Abstract Number: 1853 • ACR Convergence 2022

    A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease

    Mark Yun, Brianne Navetta-Modrov, Hafsa Nomani, Jie Yang and QingPing Yao, Stony Brook University, Stony Brook, NY

    Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…
  • Abstract Number: 2076 • ACR Convergence 2022

    Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus

    Zahi Touma1, Sheena Kayaniyil2, Anna Parackal2, Dennisse Bonilla1, Jiandong Su1, Christina Qian3, Sally Miller3, Shelagh Szabo3 and Shelly Chandran2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2AstraZeneca, Mississauga, ON, Canada, 3Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada

    Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology